Navigation Links
The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Date:11/1/2013

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML).  As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug.  Those patients who are responding well to ponatinib, and who are not eligible for therapeutic alternatives, may be able to obtain ponatinib on a compassionate use basis, but need to speak with their oncologists immediately.

We are here to advise patients how the recent news applies to them and what discussions to have with their physicians.  Patients can contact LLS's Information Resource Center at 1-800-955-4572, Monday through Friday from 9 a.m. to 6 p.m. ET.

LLS recognizes the need and urgency for new treatments for CML.  In 2013, we committed $1.7 million to CML research ranging from basic science to clinical research on how best to use new therapies.

"The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for blood cancer patients," said Mark Velleca, MD, PhD, chief policy and advocacy officer for LLS.  "As such, we felt it was important to comment on this important access issue.  Working with CML physicians and other advocacy groups, we have requested that FDA facilitate continued access to ponatinib for certain patients – such as those in blast crisis – for whom interruption of therapy could be extremely detrimental."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org

Scott Orstad
(914) 821-8873
Scott.orstad@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
4. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
5. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
6. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
9. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
11. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):